Save time and money with
Med Tech Market Research

MedTech Business intelligence
supplied by GlobalData

  Latest reports

Ischemic Cerebral Stroke Global Clinical Trials Review
The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ischemic Cerebral Stroke. Aug 2014

Multiple Sclerosis Global Clinical Trials Review
The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Multiple Sclerosis. Aug 2014

Market forecast for Aricept
Eisai’s Aricept (donepezil hydrochloride) is a piperidine derivative that acts centrally as a reversible AChEI. 6 Dec 2013

Market forecast for Exelon
Exelon (rivastigmine, rivastigmine tartrate), which is manufactured and marketed by Novartis, is a reversible ChEI indicated for the treatment of mild to moderate dementia of the Alzheimer's type. 6 Dec 2013

Market forecast for Razadyne/ Reminyl
Razadyne (also known as Reminyl) is a reversible, competitive AChEI indicated for the treatment of mild to moderate AD. The exact MOA of galantamine is not known. 6 Dec 2013

MediFocus: Medical devices for the treatment of obesity
This report offers a comprehensive analysis of the global obesity medical device market, including development and approval of artificial fullness devices, deep brain stimulation devices, endoscopic surgical devices, gastric electrical stimulation devices. 2 Oct 2013

PharmaSphere: Asia Pacific Deal Trends, 2004–2013
An in-depth analysis of the key deals that took place in the region during the last decade. The Asia Pacific Region is increasingly seen as a potential source of revenue growth for global pharma firms. 1 Oct 2013

Nascent Alzheimer's disease biomarker market provides opportunities for pharma companies
From a commercial standpoint, the Alzheimer's disease (AD) biomarkers market is still relatively young. Biomarkers for Alzheimer's disease can be classified in terms of pathological mechanism and also in terms of the assay technology used to detect and assess the biomarker.
Read more... 5 Sept 2013

EpiCast Report: Dry Eye Syndrome — Epidemiology Forecast to 2022
Dry eye syndrome, also known as keratoconjunctivitis sicca (KCS), is a multi-factorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. It results in symptoms of discomfort such as visual disturbance and tear film instability.

PharmaFocus: Vaccine Adjuvants in Infectious Disease
Originally discovered by Glenny in the 1920s, vaccine adjuvants have remained the pharmaceutical industry’s “dirty little secret”. Today, vaccine adjuvants are credited with helping to bolster the immune response in the host post-vaccination.

EpiCast Report: Alzheimer’s Disease — Epidemiology Forecast to 2022
The global prevalence of dementia is estimated to be 3.9% in people age 60 years and older, with an overall Alzheimer’s disease prevalence of 9.7% in the US, 4.4% in Europe, and 3.4% in developing countries.

PharmaLeaders: CRO benchmark report — financial benchmarking & competitive landscape assessment of leading CROs
Analysis of the key drivers and trends shaping the global CRO market; including biologics manufacturing, emerging markets, and eClinical technologies.

EpiCast: Chronic Kidney Disease — Epidemiology Forecast to 2022
The Chronic Kidney Disease EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of chronic kidney disease in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast (2012–2022) of the prevalent cases of chronic kidney disease segmented by age.

Type 2 diabetes – global drug forecast and market analysis to 2022
Overview of Type 2 diabetes, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. Annualized therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2022.

Netherlands embracing generics to counter growing healthcare costs
With the elderly making up an ever greater share of the country’s population, the Netherlands is increasingly supporting its generics sector in an attempt to address mounting healthcare costs, says a new report from industry experts GlobalData.

Denmark healthcare market bouncing back after recession
The Danish healthcare market is showing healthy signs of recovery following the crippling global financial crisis of 2008, says the latest report from business intelligence providers GlobalData: Healthcare, Regulatory and Reimbursement Landscape — Denmark.

Nanotechnology Cookbook. Practical, Reliable and Jargon-free Experimental Procedures. Elsevier Science and Technology, June 2012, Pages: 324. 100+ detailed recipes for synthesis of basic nanostructured materials, enables readers to pick up the book and get started on a preparation immediately. A cookbook, by design and structure the work is easy to use, familiar and compact.

main-imageRheumatoid Arthritis Therapeutics — Pipeline Assessment and Market Forecasts to 2018
Rheumatoid Arthritis Therapeutics Market is Forecast to Show Moderate Growth Until 2018. GlobalData’s analysis suggests that the global rheumatoid arthritis therapeutics market was worth $10.3 billion in 2010 and forecast to grow at a CAGR of 3.8% to reach $13.8 billion by 2018. The high growth rate during 2005-2010 is primarily attributed to the launch of biologics such as Enbrel (etanercept), Remicade(infliximab), Humira (adalimumab) and Rituxan (rituximab). Read more ...


To top



To top